What are the ELAINE studies?
![](/wp-content/themes/elainestudy/images/es-home-page-elaine3-logo-268x241.png)
The ELAINE studies are investigating an oral drug, lasofoxifene, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1) mutation.
ELAINE-1 and ELAINE-2 are active with enrollment complete. Enrollment is currently open for ELAINE-3, a large, randomized, phase 3 study with clinical trial sites across the United States, Europe, Asia-Pacific, Israel, and Canada.
![elaine](/wp-content/themes/elainestudy/images/es-elaine-round-347x347.png)
Who is Elaine?
The ELAINE studies are dedicated in memory of Elaine Davidson Nemzer, MD, the sister of Sermonix co-founder Miriam Davidson Portman, MD. Elaine was a brilliant and compassionate child psychiatrist whose life was cut short by metastatic breast cancer at the age of 47. She was the author of several textbook chapters on psychiatry and a dedicated therapist, teacher, colleague, wife, mother, sister, and friend. Even during her illness, she was a source of comfort and hope to all those she encountered, and her spirit continues to serve as an inspiration to the Sermonix team, filling us with passion and purpose.
![Sermonix_ElaineStudy](/wp-content/themes/elainestudy/images/es-purple-es1-logo-245x220.png)
About the ELAINE-1 study
Primary Objective:
Evaluated the impact on progression-free survival (PFS) of 5 mg of oral lasofoxifene versus injectable fulvestrant, a treatment commonly used in this population.1
103
total patients
were enrolled in ELAINE-11
35
US trial sites
+
45
international
including Mayo Clinic, Ohio State University, Washington University School of Medicine, and Sheba Medical Center (Israel)1
![logos-bottom](/wp-content/themes/elainestudy/images/es-ohio-state-logo-291x164.png)
![logos-bottom](https://discoverelaine.com/wp-content/themes/elainestudy/images/washington-logo-225x184.png)
![logos-bottom](https://discoverelaine.com/wp-content/themes/elainestudy/images/home-logo-group-1b-562x377.png)
Sermonix Pharmaceuticals and associated logos are trademarks of Sermonix Pharmaceuticals. All other trademarks are property of their respective owners.
![Sermonix_ElaineStudy2](/wp-content/themes/elainestudy/images/es-purple-es2-logo-245x220.png)
About the ELAINE-2 study
Primary objective:
Evaluate the safety and efficacy of the combination of lasofoxifene and abemaciclib.4
Proudly partnering with Lilly® and Verzenio®
29
total patients
were enrolled in ELAINE-24
15
trial sites
including MD Anderson, Mayo Clinic, and Cleveland Clinic4
![logos-bottom](/wp-content/themes/elainestudy/images/home-logo-group-2-565x313.png)
Sermonix Pharmaceuticals and associated logos are trademarks of Sermonix Pharmaceuticals. All other trademarks are property of their respective owners.
References: 1. Data on file. Sermonix Pharmaceuticals; 2023. 2. Cogliati V, Capici S, Pepe FF, et al. Life (Basel). 2022;12(3):378. 3. Angus L, Beije N, Jager A, Martens JW, Sleijfer S. Cancer Treat Rev. 2017;52:33-40. 4. Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation. ClinicalTrials.gov identifier: NCT04432454. Updated June 7, 2022. Accessed July 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04432454
Send me the latest news
By subscribing, you agree to receive the latest news and updates from us.